Ibuzatrelvir

Ibuzatrelvir (PF-07817883), a second-generation, orally bioavailable, is SARS-CoV-2 main protease (Mpro and 3CLpro) inhibitor with improved metabolic stability. Ibuzatrelvir has demonstrated pan-human coronavirus antiviral activity and off-target selectivity profile in vitro and in preclinical animal studies. Ibuzatrelvir is well tolerated with a safety profile similar to placebo and prevents viral infection and transmission. Ibuzatrelvir can be used to inhibit COVID-19[1][2][3][4].

Product Specifications

CAS Number

[2755812-39-4]

Product Name Alternative

PF-07817883

UNSPSC

12352005

Target

SARS-CoV; Virus Protease

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/ibuzatrelvir.html

Purity

99.90

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

COC(N[C@@H](C(C)(C)C)C(N1[C@@H](C[C@H](C1)C(F)(F)F)C(N[C@H](C#N)C[C@H]2C(NCC2)=O)=O)=O)=O

Molecular Formula

C21H30F3N5O5

Molecular Weight

489.49

References & Citations

[1]Owen, et al. Preparation of peptidomimetic nitriles as SARS-CoV-2 3CL protease inhibitors and methods for the treatment of COVID-19. World Intellectual Property Organization, WO2021250648 A1. 2021-12-16.|[2]Mahta Mortezavi, et al. Virologic Response and Safety After Oral Administration of Ibuzatrelvir, a Novel SARS-CoV-2 Mpro Inhibitor, in Non-Hospitalized Adults With Symptomatic COVID-19. European Congress of Clinical Microbiology and Infectious Disease (ECCMID) 2024; 2024 April 27-30.|[3]Westberg M, et al. An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations[J]. Sci Transl Med. 2024 Mar 13;16 (738) :eadi0979.|[4]Allerton CMN, et al. A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19[J]. J Med Chem. 2024 Apr 30.